Abstract:The Chimera antigen receptor (CAR)-T cell therapy has gained great success in the clinic. However, there are still major challenges for its wider applications in a variety of cancer types including lack of effectiveness due to the highly complex tumor microenvironment, and the forbiddingly high cost due to the personalized manufacturing procedures. In order to overcome these hurdles, numerous efforts have been spent focusing on optimizing Chimera antigen receptors, engineering and improving T cell capacity, exploiting features of subsets of T cell or NK cells, or making off-the-shelf universal cells. Here, in the first part, we developed induced pluripotent stem cells (iPSCs)-derived, CAR-expressing macrophage cells (CAR-iMac). CAR expression confers antigen-dependent macrophage functions such as expression and secretion of cytokines, enhanced phagocytosis of tumor cells, and in vivo anticancer cell activity. This technology platform for the first time provides an unlimited source of iPSC-derived engineered CAR-macrophage cells which could be utilized to eliminate cancer cells. In the second part, we focus on the "second generation” of CAR-iMac and its applications in solid tumors. Therapeutic effects of CAR-T cells on solid tumors remains to be improved. CAR-macrophages have attracted much attention in solid tumor, given their ability to phagocytize tumor cells and their immunomodulatory capacities in the TME. The first generation of engineered CAR-iMac demonstrated that the CAR could stimulate macrophage phagocytosis in a tumor antigen-dependent way. For the second generation of CAR-iMac, after careful screening and rational designs, we genetically engineered iPSC-derived macrophages (iMACs) with Toll-like Receptor intracellular TIR domain-containing CARs against EGFRvIII and GPC3, which yielded an enhanced antitumor effect in two different tumor types . Moreover, CD3ζ-TIR-CAR, the second generation design of TIR-based dual signaling CAR, endowed iMACs with both target engulfment/trogocytosis capacity against antigen-expressing solid tumor cells, and potency of antigen-dependent M1-polarization and M2-like state resistance in an NF-κB dependent manner. Taken together, we established the next generation CAR-iMACs equipped with enhanced phagocytosis and polarization capacity for better antitumor functions in treating liquid and solid tumors. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal

Injectable Supramolecular Hydrogels for in Situ Programming of Car-T Cells Toward Solid Tumor Immunotherapy

Injectable Supramolecular Hydrogels for in Situ Programming of Car‐T Cells Towards Solid Tumor Immunotherapy

Injectable Porous Microchips with Oxygen Reservoirs and an Immune-Niche Enhance the Efficacy of CAR T Cell Therapy in Solid Tumors

Injectable and photocurable CAR-T cell formulation enhances the anti-tumor activity to melanoma in mice

Delivering CAR‐T cells into solid tumors via hydrogels

Delivery of CAR-T Cells in a Transient Injectable Stimulatory Hydrogel Niche Improves Treatment of Solid Tumors

Promoting The Recruitment, Engagement, And Reinvigoration of Effector T Cells via An Injectable Hydrogel with A Supramolecular Binding Capability for Cancer Immunotherapy

A Tetramethylpyrazine Releasing Hydrogel Can Potentiate CAR-T Cell Therapy Against Triple Negative Breast Cancer by Reprogramming Tumor Vasculatures

The Second Generation of Human Ipsc-Derived CAR-Macrophages for Immune Cell Therapies in Liquid and Solid Tumors

Chemokine‐Based Injectable Navigation System for Enhancing CAR‐T Cell Therapy Against Solid Tumors

Programming Injectable DNA Hydrogels Yields Tumor Microenvironment-Activatable and Immune-Instructive Depots for Augmented Chemo-Immunotherapy

Tumor Lysates-Constructed Hydrogel to Potentiate Tumor Immunotherapy

Interference Rna (Rnai)-Based Silencing of Endogenous Thrombopoietin Receptor (mpl) in Dami Cells Resulted in Decreased Hnudc-Mediated Megakaryocyte Proliferation and Differentiation

Localized Chemotherapy Based on Injectable Hydrogel Boosts the Antitumor Activity of Adoptively Transferred T Lymphocytes In Vivo

Bioorthogonal Equipping CAR-T Cells with Hyaluronidase and Checkpoint Blocking Antibody for Enhanced Solid Tumor Immunotherapy

Toroidal-spiral particles as a CAR-T cell delivery device for solid tumor immunotherapy

Lymph node-biomimetic scaffold boosts CAR-T therapy against solid tumor

A CAR T-inspiring platform based on antibody-engineered exosomes from antigen-feeding dendritic cells for precise solid tumor therapy

Elevating the potential of CAR-T cell therapy in solid tumors: exploiting biomaterials-based delivery techniques

Programming of in Situ Tumor Vaccines via Supramolecular Nanodrug/Hydrogel Composite and Deformable Nanoadjuvant for Cancer Immunotherapy

A prodrug hydrogel with tumor microenvironment and near-infrared light dual-responsive action for synergistic cancer immunotherapy